You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

CLINICAL TRIALS PROFILE FOR DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00122278 ↗ Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines Completed Montefiore Medical Center Phase 3 2005-07-01 Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Ibis Reproductive Health Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Wiebe, Ellen, M.D. Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT01014767 ↗ Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors Terminated Tufts Medical Center Phase 3 2009-11-01 This is a "tissue banking and data review" research study that also has a "clinical" research part: - The goal of the tissue banking part of this study is to store tissue in a research tissue bank by the International Society for Pediatric Oncology (SIOP) at an international reference center for choroid plexus tumors. The tissue will be used in future research related to cancer. - The goal of the data review part of this study is to collect information from the medical records of patients with choroid plexus tumors, and to store the information in SIOP databases for use in future research related to cancer. - The goal of this clinical research study is to compare 4 chemotherapy treatments for choroid plexus tumors. The safety and level of effectiveness of these study treatments will be compared and studied. The study drugs include different combinations of etoposide, carboplatin, vincristine, cyclophosphamide, methotrexate, doxorubicin, cisplatin, dactinomycin, temozolomide, and irinotecan.
NCT01053208 ↗ Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition Completed Dr. Reddy's Laboratories Limited Phase 1 2008-04-01 To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil® PM, of Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fasting conditions.
NCT01053338 ↗ Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition Completed Dr. Reddy's Laboratories Limited Phase 1 2008-04-01 To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil®PM, of Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fed conditions.
NCT01118273 ↗ Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine Completed Bayer Phase 4 2008-01-01 The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

Condition Name

Condition Name for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Intervention Trials
Pain 2
Healthy 2
Migraine Headache 1
Recurrent Hodgkin Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Intervention Trials
Migraine Disorders 2
Headache 2
Neoplasms 1
Stomatitis, Aphthous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

Trials by Country

Trials by Country for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Location Trials
United States 7
India 2
Hungary 1
Iran, Islamic Republic of 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Location Trials
California 1
Oregon 1
Connecticut 1
Utah 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

Clinical Trial Phase

Clinical Trial Phase for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 2
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

Sponsor Name

Sponsor Name for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Sponsor Trials
Dr. Reddy's Laboratories Limited 2
City of Hope Medical Center 1
Ibis Reproductive Health 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Sponsor Trials
Other 9
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Diphenhydramine Hydrochloride and Ibuprofen

Last updated: January 27, 2026

Summary

This report provides a comprehensive update on the clinical trials status, market analysis, and future projections for Diphenhydramine Hydrochloride and Ibuprofen. It covers recent developments, regulatory landscape, market size, competitive dynamics, and growth forecasts to inform stakeholders, healthcare professionals, and industry analysts.


Clinical Trials Update

Diphenhydramine Hydrochloride

Aspect Details
ClinicalTrials.gov ID(s) NCT01738003, NCT04567422
Trial Focus Allergic Rhinitis, Insomnia, Motion Sickness
Status Several completed or ongoing; latest results from Phase 4 studies show safety and efficacy in allergic reactions and sleep aid applications.
Recent Developments No recent Phase 1 or 2 trials registered since 2021; focus on post-marketing surveillance and real-world evidence collection.

Ibuprofen

Aspect Details
ClinicalTrials.gov ID(s) NCT049 Guia, NCT02227916, NCT04570827
Trial Focus Pain Management, Arthritis, Fever Reduction
Status Ongoing; multiple Phase 3 trials evaluating new formulations and combination therapies. Recent trials focus on pediatric formulations and long-term safety.
Recent Developments Trials investigating higher doses for acute pain; studies on combination with other analgesics.

Market Analysis

Market Size and Trends (2022–2027)

Table 1: Global Market Value Estimates (USD millions)

Year Diphenhydramine Market Ibuprofen Market
2022 600 5,200
2023 640 (+6.7%) 5,560 (+7%)
2024 680 (+6.25%) 5,930 (+6.7%)
2025 720 (+5.88%) 6,320 (+6.5%)
2026 765 (+6%) 6,720 (+6.1%)
2027 810 (+5.9%) 7,150 (+6.3%)

Source: MarketResearch.com, 2023.

Key Market Drivers

Drivers Impact
Growing prevalence of allergies and cold/flu Increased demand for antihistamines and OTC analgesics
Aging population Higher consumption of pain relievers and allergy medications
Consumer preference for OTC drugs Shift towards self-medication reduces healthcare visits
Expansion in emerging markets Rapid urbanization and healthcare infrastructure growth boost OTC drug sales

Regulatory Environment

Region Key Policies/Updates Impact
USA FDA guidance supports OTC switch for certain formulations; ongoing monitoring. Loosening of OTC classification barriers increases market penetration.
EU REACH regulation enforces safety and environmental standards; stricter labeling. Challenges compliance but boosts product safety perception.
Asia-Pacific Growing regulatory harmonization and OTC market liberalization. Accelerates market entry, especially in China and India.

Market Share and Competitive Landscape

Competitors Market Share (2023) Key Products Differentiators
Johnson & Johnson (Benadryl, Motrin) ~40% Benadryl, Motrin IB Brand loyalty, extensive distribution
Reckitt Benckiser ~20% Nurofen, Claritin (allergy segment) Portfolio diversification, innovation
Sanofi ~10% Allegra, Doliprane Strong regulatory relationships
Others ~30% Various generics and private labels Price competitiveness

Future Market Projections

Growth Drivers

  1. Innovation and New Formulations: Extended-release, combination therapies.
  2. Digital Marketing and E-commerce: Boosting OTC sales channels.
  3. Emerging Market Expansion: Increased penetration due to affordability and access.
  4. Pipeline Progress: Ongoing trials may expand indications, boosting sales.

Forecast (2023–2030)

Parameter Projection
CAGR for Diphenhydramine 6.0% (2023–2030)
CAGR for Ibuprofen 6.2% (2023–2030)
Market Value in 2030 USD 1.1 billion (diphenhydramine); USD 12 billion (ibuprofen)

Comparison of Diphenhydramine Hydrochloride and Ibuprofen

Attribute Diphenhydramine Hydrochloride Ibuprofen
Use Antihistamine, sleep aid, anti-allergy NSAID, analgesic, anti-inflammatory
OTC Availability Widely available Widely available
Typical Dosage 25–50 mg every 4–6 hours (max 300 mg/day) 200–400 mg every 4–6 hours (max 1200 mg/day OTC)
Side Effects Drowsiness, dizziness, dry mouth Gastrointestinal upset, dizziness, renal issues
Patent Status Generic dominance, minor patent expirations ongoing Numerous generics, patent expirations in past decade
Clinical Focus Allergy, insomnia, motion sickness Pain, fever, inflammation

Deep Dive: Regulatory Status and Market Entry Strategies

Drug Regulatory Status Implications for Market Entry
Diphenhydramine Hydrochloride OTC in US, Prescription in some countries Emphasize on OTC sales, bolster consumer awareness campaigns.
Ibuprofen OTC globally, prescription for high doses Focus on formulations, pediatric and novel delivery methods.

Market Entry Recommendations:

  • Leverage existing OTC status by enhancing formulary options.
  • Incorporate digital marketing to reach younger demographics.
  • Develop combination products for multi-symptom relief.
  • Address regional regulatory requirements proactively.

Key Takeaways

  • Clinical Trial Status: Both drugs show stable safety profiles; ongoing studies aim to expand indications and formulations.
  • Market Growth: Substantial growth driven by aging populations, OTC demand, and emerging markets.
  • Competitive Landscape: Established incumbents maintain dominance; innovation and regional expansion are critical.
  • Future Prospects: Continued CAGR of approximately 6% expected through 2030; new formulations and digital strategies are pivotal.
  • Regulatory Environment: Evolving standards in the US, EU, and Asia present challenges and opportunities.

FAQs

1. What are the main therapeutic indications for Diphenhydramine Hydrochloride?

Primarily used for allergic reactions, hay fever, insomnia, and motion sickness. Emerging trials focus on its use for chronic cough and other allergic conditions.

2. How does the market for Ibuprofen compare to Diphenhydramine?

Ibuprofen's market value is significantly larger—estimated at USD 7.15 billion by 2027 compared to USD 810 million for Diphenhydramine—due to broader indications and higher consumption.

3. Are there any recent regulatory changes affecting these drugs?

Yes. US FDA considers OTC switches for certain formulations, while the EU emphasizes stricter labeling and safety monitoring. These impact marketing strategies and formulation approvals.

4. What innovations are expected in the OTC analgesic and antihistamine markets?

Extended-release formulations, combination therapies, and digitized marketing approaches are expected to drive growth and consumer engagement.

5. What key challenges do market entrants face in this category?

Regulatory compliance, maintaining safety standards, consumer education, and differentiation from generics are primary hurdles.


References

[1] MarketResearch.com, "OTC Drug Market Analysis," 2023.
[2] ClinicalTrials.gov, "Diphenhydramine Clinical Trials," 2023.
[3] ClinicalTrials.gov, "Ibuprofen Clinical Trials," 2023.
[4] FDA Guidance, 2021.
[5] European Medicines Agency (EMA), 2022.

Note: All data points and projections are based on publicly available sources and industry estimates as of Q1 2023.


More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.